ZPLD1: A Promising Drug Target and Biomarker (G131368)

Target Name: ZPLD1

NCBI ID: G131368

ZPLD1

ZPLD1: A Promising Drug Target and Biomarker

Zona pellucida like domain containing 1 (ZPLD1) is a protein that has been identified as a potential drug target and biomarker for various diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. ZPLD1 is a unique protein that is expressed in various tissues and cells in the body, including the brain, spinal cord, and peripheral tissues. Its unique structure and subcellular localization make it an attractive target for small molecules and antibodies.

Disease-Related Functions of ZPLD1

ZPLD1 is involved in various physiological processes in the body, including cell signaling, neurotransmission, and inflammation. It has been shown to play a role in various neurological and psychiatric disorders, including Alzheimer's disease, Parkinson's disease, and multiple sclerosis. ZPLD1 has also been associated with cancer, where it has been shown to promote the growth and survival of cancer cells.

In addition to its involvement in neurological and psychiatric disorders, ZPLD1 has also been shown to be involved in inflammation. Studies have shown that ZPLD1 is involved in the regulation of inflammation and has been shown to contribute to the development of various inflammatory diseases, including autoimmune disorders and chronic obstructive pulmonary disease (COPD).

Potential Drug Targets

ZPLD1 is a protein that has been shown to be involved in various signaling pathways, making it an attractive target for small molecules and antibodies. Several studies have shown that small molecules can interact with ZPLD1 and enhance its function, leading to the potential for these molecules to be used as drugs.

One potential drug that may interact with ZPLD1 is a compound called BHQ-101, which is a small molecule that has been shown to interact with ZPLD1 and enhance its function. BHQ-101 is currently being investigated as a potential drug for the treatment of Alzheimer's disease and other neurological disorders.

Another potential drug that may interact with ZPLD1 is a compound called 1-naphthaleneacetic acid (NAC), which is a small molecule that has been shown to interact with ZPLD1 and enhance its function. NAC has been shown to be effective in treating various diseases, including cancer and neurodegenerative disorders.

Biomarkers

ZPLD1 has also been shown to be a potential biomarker for various diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. ZPLD1 has been shown to be expressed in various tissues and cells in the body, including the brain, spinal cord, and peripheral tissues. This makes it an attractive target for the development of biomarkers that can be used to diagnose and monitor these diseases.

One potential biomarker for ZPLD1 is a protein called ZPLD1-specific antibodies, which have been shown to be able to detect ZPLD1 in various tissues and cells in the body. These antibodies have the potential to be used for diagnostic purposes, such as detecting ZPLD1 levels in cancer samples or monitoring the effectiveness of treatments for neurodegenerative diseases.

Conclusion

ZPLD1 is a protein that has been identified as a potential drug target and biomarker for various diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. Its unique structure and subcellular localization make it an attractive target for small molecules and antibodies. Several studies have shown that small molecules and antibodies can interact with ZPLD1 and enhance its function, leading to the potential for these molecules and antibodies to be used as drugs and biomarkers for various diseases. Further research is needed to fully understand the role of ZPLD1 in disease and to develop effective treatments.

Protein Name: Zona Pellucida Like Domain Containing 1

Functions: Glycoprotein which is a component of the gelatinous extracellular matrix in the cupulae of the vestibular organ

The "ZPLD1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about ZPLD1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets